Autopsy report · NCT05708924

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

“Product withdrawn from clinical development”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Cancer; Solid Tumor; Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Interventions

FT538; Enoblituzumab

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A
  “The clinical trial was withdrawn due to a commercial decision.” (77% match in meaning)
• 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
  “Pharmaceutical Company withdrew support and investigational product” (71% match in meaning)
• Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
  “This study was withdrawn due to a strategic business decision; no patients were enrolled.” (68% match in meaning)
• Study to Assess an Interphase Cycle With Flotetuzumab.
  “Withdrawal of MacroGenics (pharmaceutical company)” (67% match in meaning)
• SMMART Adaptive Clinical Treatment (ACT) Trial
  “Withdrawn due to a change in therapeutic interventions.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.